Click here for slides on this topic


Pancreatitis

Inflammation of the pancreas
The following content matched the glossary term: Pancreatitis

No Increased Risk of Pancreatic Cancer With Incretins

Top

Data presented at EASD 2015 show no causal association between the use of incretin based therapies—DPP-4 inhibitors and GLP-1 receptor agonists—and pancreatitis or pancreatic cancer

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.



Slide Library Results

Search Results for: Pancreatitis Slides Found: 25
Medical Comorbidities Associated with Obesity
Association Between Obesity and Comorbidities
SAVOR-TIMI 53: Safety Endpoints
EXAMINE: Adverse Events
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
SAVOR TIMI Saxagliptin Pancreatitis | NDEI
SAVOR TIMI 53 Pancreatitis Risk Factors Saxagliptin DPP-4 | NDEI
No Pancreatic Cancer Signal Saxagliptin DPP-4 SAVOR TIMI | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
Reports of Acute Pancreatitis Type 2 Diabetes Drugs | NDEI
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
Safety of Dulaglutide & Insulin Glargine Pancreatitis AWARD-2 | NDEI
AWARD-2 Similar Adverse Events With Dulaglutide & Insulin Glargine Type 2 Diabetes | NDEI
Treating Dyslipidemia in Women NLA Cholesterol Guidelines | CCMD
Cholesterol Treatment Algorithm to Reduce ASCVD NLA Guidelines | CCMD
LEADER Cardiovascular Safety of Liraglutide CVOT PPT | NDEI